Press release content from Accesswire. The AP news staff was not involved in its creation.
Evotec And Related Sciences Enter Integrated Drug Discovery and Development Partnership
February 9, 2021 GMT
PARTNERSHIP COMBINES RELATED SCIENCES’ COLLABORATIVE SCIENCE MODEL AND DATA-DRIVEN APPROACH TO IDENTIFYING BIOLOGICAL BREAKTHROUGHS WITH EVOTEC’S INTEGRATED PLATFORM TO DRIVE INNOVATIVE MULTIMODALITY DRUG DISCOVERY FROM TARGET TO CLINIC
EVOTEC WILL BENEFIT FROM SUCCESS THROUGH MILESTONES, ROYALTIES AND FOUNDING EQUITY STAKES IN ALL RELATED SCIENCES ASSETS DEVELOPED WITHIN THIS COLLABORATION
HAMBURG, GERMANY / ACCESSWIRE / February 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 .
AzurRx BioPharma, Inc.February 9, 2021 GMT
Phase 2 Study of oral niclosamide planned for 1H 2021
DELRAY BEACH, Fla., Feb. 09, 2021 (GLOBE NEWSWIRE) AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 2 clinical trial evaluating a proprietary formulation of micronized niclosamide as a treatment for COVID-19-associated gastrointestinal (GI) infections.
NEW YORK (AP) — Fox News Media CEO Suzanne Scott signed a new contract Tuesday and the company said it will continue its “center right” programming mix despite a recent
NEW YORK (AP) Fox News Media CEO Suzanne Scott signed a new contract Tuesday and the company said it will continue its “center right” programming mix despite a recent